At the recent capital markets day, SynAct Pharma presented its strategic roadmap for resomelagon, detailing a dual strategy targeting rheumatoid arthritis and respiratory infections. Supported by external clinical expertise and a robust financial position, management highlighted the candidate's potential to redefine inflammation treatment through resolution therapy. With the phase IIb ADVANCE study nearing its primary readout in June, the company remains focused on data-driven business development. BioStock contacted CEO Jeppe Øvlesen for a comment.
Read the full interview at biostock.se:
SynAct Pharma lays out dual strategy for resolution therapy at capital markets day
This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/